EpCAM silencing suppresses aggressive phenotypes and induces partial redifferentiation in anaplastic thyroid cancer cells
PLOS One · 05.03.2026 · 21 (3) · e0344276
DOI: 10.1371/journal.pone.0344276 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 05.03.2026. Verfasst von Teruo Nakamura und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan. Hauptthemen laut MEDLINE: Epithelial Cell Adhesion Molecule, Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, Cell Differentiation. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Anaplastic thyroid cancer (ATC) is a rare but highly aggressive malignancy with a dismal prognosis. Although recent advances in targeted therapies have modestly improved survival, the molecular mechanisms driving ATC progression remain incompletely elucidated. Epithelial cell adhesion molecule (EpCAM), a multifunctional cell-surface protein, is implicated in proliferation, migration, and stemness in various cancers. However, its role in thyroid cancer progression remains unclear. In this study, we investigated the function of EpCAM in thyroid cancer cell lines of varying differentiation status. EpCAM expression was significantly elevated in ATC cell lines compared with differentiated thyroid cancer (DTC) lines. EpCAM knockdown by siRNA suppressed proliferation, adhesion, motility, and invasion in ATC cells, but had minimal effects on DTC cells. Morphological analyses revealed that EpCAM silencing induced differentiation features, including follicle-like structure formation and increased expression of thyroid differentiation markers such as thyroglobulin and PAX8 in ATC cells. Furthermore, EpCAM inhibition decreased mesenchymal marker expression, reduced filopodia formation, and suppressed extravasation of cancer cells into the lung in an in vivo mouse model. Mechanistically, EpCAM knockdown attenuated epithelial–mesenchymal transition (EMT)-related pathways but did not affect major proliferation signaling cascades in ATC cells. These findings suggest that EpCAM promotes dedifferentiation and metastatic potential in ATC through EMT modulation. Our results provide new insights into the role of EpCAM in thyroid cancer biology and highlight its potential as a therapeutic target in ATC. Further studies are warranted to elucidate the mechanisms linking EpCAM to anaplastic transformation and to explore the therapeutic efficacy of EpCAM-targeting strategies in aggressive thyroid cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, Asahi, Matsumoto, Japan.
ORCID-Profile: Ken-Ichi Ito
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Nakamura, T., Shibata, T., & Ito, K. I. (2026). EpCAM silencing suppresses aggressive phenotypes and induces partial redifferentiation in anaplastic thyroid cancer cells. PLOS One, 21(3), e0344276. https://doi.org/10.1371/journal.pone.0344276
Vancouver
Nakamura T, Shibata T, Ito KI. EpCAM silencing suppresses aggressive phenotypes and induces partial redifferentiation in anaplastic thyroid cancer cells. PLOS One. 2026;21(3):e0344276. doi:10.1371/journal.pone.0344276
BibTeX
@article{Nakamura2026,
author = {Nakamura, Teruo and Shibata, Tomohiro and Ito, Ken-Ichi},
title = {EpCAM silencing suppresses aggressive phenotypes and induces partial redifferentiation in anaplastic thyroid cancer cells},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {3},
pages = {e0344276},
doi = {10.1371/journal.pone.0344276}
}
EUVIMED